| RS2068126785 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068126851 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068130178 |
COL4A5
|
Health Risk |
Pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068193669 |
ATRX
|
Health Risk |
Likely pathogenic |
Intellectual disability-hypotonic facies syndrome, X-linked |
| RS2068213764 |
RPS6KA3
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2068243273 |
SLC46A1
|
Health Risk |
Conflicting classifications of pathogenicity |
Congenital defect of folate absorption, Congenital defect of folate absorption |
| RS2068301622 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068301848 |
OTC
|
Health Risk |
Likely pathogenic |
— |
| RS2068302240 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068302365 |
OTC
|
Health Risk |
Likely pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068302412 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068314699 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068315546 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068315570 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068329229 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068330297 |
COL4A5
|
Health Risk |
Likely pathogenic |
— |
| RS2068330799 |
COL4A5
|
Health Risk |
Pathogenic |
Alport syndrome, Alport syndrome |
| RS2068331233 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2068332131 |
COL4A5
|
Health Risk |
Pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068333361 |
COL4A5
|
Health Risk |
Pathogenic |
Alport syndrome, Alport syndrome |
| RS2068375565 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068379887 |
SDCCAG8
|
Health Risk |
Conflicting classifications of pathogenicity |
Bardet-Biedl syndrome 16, Senior-Loken syndrome 7 |
| RS2068409652 |
COL4A5
|
Health Risk |
Likely pathogenic |
— |
| RS2068413590 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068436110 |
COL4A5
|
Health Risk |
Pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068437273 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068449960 |
TTN
|
Health Risk |
Likely pathogenic |
Dilated cardiomyopathy 1G, Autosomal recessive limb-girdle muscular dystrophy type 2J |
| RS2068485732 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068486155 |
OTC
|
Health Risk |
Likely pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068486828 |
OTC
|
Health Risk |
Likely pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068487136 |
OTC
|
Health Risk |
Conflicting classifications of pathogenicity |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068501144 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068501410 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068501518 |
OTC
|
Health Risk |
Likely pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068501940 |
OTC
|
Health Risk |
Pathogenic/Likely pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068502349 |
OTC
|
Health Risk |
Likely pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068502421 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068502738 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068529327 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068529566 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068529696 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068530106 |
OTC
|
Health Risk |
Likely pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068530290 |
OTC
|
Health Risk |
Likely pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068530385 |
OTC
|
Health Risk |
Likely pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068537554 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068539626 |
COL4A5
|
Health Risk |
Conflicting classifications of pathogenicity |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068539903 |
COL4A5
|
Health Risk |
Likely pathogenic |
Alport syndrome, Alport syndrome |
| RS2068545306 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068545602 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068567564 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068570435 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2068571470 |
COL4A5
|
Health Risk |
Pathogenic |
Alport syndrome, Alport syndrome |
| RS2068574381 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2068585706 |
CHRNA4
|
Health Risk |
Conflicting classifications of pathogenicity |
Autosomal dominant nocturnal frontal lobe epilepsy, Autosomal dominant nocturnal frontal lobe epilepsy |
| RS2068592611 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068592875 |
OTC
|
Health Risk |
Pathogenic |
Ornithine carbamoyltransferase deficiency, Ornithine carbamoyltransferase deficiency |
| RS2068604683 |
TTN
|
Health Risk |
Likely pathogenic |
Dilated cardiomyopathy 1G, Autosomal recessive limb-girdle muscular dystrophy type 2J |
| RS2068606445 |
TAFAZZIN
|
Health Risk |
Likely pathogenic |
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2068606932 |
TAFAZZIN
|
Health Risk |
Pathogenic/Likely pathogenic |
Cardiomyopathy, 3-Methylglutaconic aciduria type 2 |
| RS2068634140 |
GATA2
|
Health Risk |
Conflicting classifications of pathogenicity |
Monocytopenia with susceptibility to infections, Deafness-lymphedema-leukemia syndrome |
| RS2068635192 |
GATA2
|
Health Risk |
Conflicting classifications of pathogenicity |
Monocytopenia with susceptibility to infections, Deafness-lymphedema-leukemia syndrome |
| RS2068635493 |
GATA2
|
Health Risk |
Pathogenic |
Deafness-lymphedema-leukemia syndrome, GATA2 deficiency with susceptibility to MDS/AML |
| RS2068635607 |
GATA2
|
Health Risk |
Pathogenic |
Deafness-lymphedema-leukemia syndrome, Monocytopenia with susceptibility to infections |
| RS2068649745 |
PAFAH1B1
|
Health Risk |
Likely pathogenic |
Lissencephaly, Lissencephaly |
| RS2068650679 |
RPS6KA3
|
Health Risk |
Pathogenic/Likely pathogenic |
Coffin-Lowry syndrome, Coffin-Lowry syndrome |
| RS2068656783 |
PRKCG
|
Health Risk |
Likely pathogenic |
Spinocerebellar ataxia type 14, Spinocerebellar ataxia type 14 |
| RS2068659442 |
PRKCG
|
Health Risk |
Likely pathogenic |
— |
| RS2068659829 |
COL4A5
|
Health Risk |
Pathogenic |
— |
| RS2068660300 |
COL4A5
|
Health Risk |
Likely pathogenic |
— |
| RS2068661291 |
GATA2
|
Health Risk |
Conflicting classifications of pathogenicity |
Deafness-lymphedema-leukemia syndrome, Monocytopenia with susceptibility to infections |
| RS2068661887 |
GATA2
|
Health Risk |
Conflicting classifications of pathogenicity |
Deafness-lymphedema-leukemia syndrome, Monocytopenia with susceptibility to infections |
| RS2068663163 |
GATA2
|
Health Risk |
Conflicting classifications of pathogenicity |
Deafness-lymphedema-leukemia syndrome, Monocytopenia with susceptibility to infections |
| RS2068678455 |
MAPK1
|
Health Risk |
Likely pathogenic |
6 conditions, 6 conditions |
| RS2068680774 |
ATP6AP1
|
Health Risk |
Pathogenic |
Immunodeficiency 47, Immunodeficiency 47 |
| RS2068685370 |
GATA2
|
Health Risk |
Pathogenic |
Deafness-lymphedema-leukemia syndrome, GATA2 deficiency with susceptibility to MDS/AML |
| RS2068696629 |
GATA2
|
Health Risk |
Conflicting classifications of pathogenicity |
Deafness-lymphedema-leukemia syndrome, Monocytopenia with susceptibility to infections |
| RS2068703521 |
MT-TS1
|
Health Risk |
Likely pathogenic |
neonatal lactic acidosis, Mitochondrial complex IV deficiency |
| RS2068705545 |
ATP6AP1
|
Health Risk |
Pathogenic |
Immunodeficiency 47, Immunodeficiency 47 |
| RS2068716907 |
MAPK1
|
Health Risk |
Pathogenic |
Noonan syndrome 13, Heart |
| RS2068716940 |
MAPK1
|
Health Risk |
Pathogenic/Likely pathogenic |
Heart, malformation of |
| RS2068717187 |
COL4A5
|
Health Risk |
Pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068717619 |
COL4A5
|
Health Risk |
Pathogenic |
Alport syndrome, Alport syndrome |
| RS2068718016 |
COL4A5
|
Health Risk |
Pathogenic/Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2068730966 |
PRKCG
|
Health Risk |
Likely pathogenic |
— |
| RS2068750338 |
GDI1
|
Health Risk |
Likely pathogenic |
Intellectual disability, X-linked 41 |
| RS2068755805 |
GDI1
|
Health Risk |
Pathogenic |
Intellectual disability, X-linked 41 |
| RS2068757385 |
GDI1
|
Health Risk |
Pathogenic |
Intellectual disability, X-linked 41 |
| RS2068797150 |
FAM50A
|
Health Risk |
Likely pathogenic |
Armfield syndrome, Armfield syndrome |
| RS2068797171 |
FAM50A
|
Health Risk |
Likely pathogenic |
Armfield syndrome, Armfield syndrome |
| RS2068797192 |
FAM50A
|
Health Risk |
Likely pathogenic |
Intellectual disability, Armfield syndrome |
| RS2068825510 |
NLRP7
|
Health Risk |
Likely pathogenic |
Hydatidiform mole, recurrent |
| RS2068937789 |
COL4A3
|
Health Risk |
Likely pathogenic |
Autosomal recessive Alport syndrome, Autosomal recessive Alport syndrome |
| RS2068946379 |
IRS4
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2068947331 |
TTN
|
Health Risk |
Likely pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2J, Dilated cardiomyopathy 1G |
| RS2068947933 |
TTN
|
Health Risk |
Conflicting classifications of pathogenicity |
Autosomal recessive limb-girdle muscular dystrophy type 2J, Dilated cardiomyopathy 1G |
| RS2069047923 |
TTN
|
Health Risk |
Likely pathogenic |
Dilated cardiomyopathy 1G, Autosomal recessive limb-girdle muscular dystrophy type 2J |
| RS2069052012 |
MAPK1
|
Health Risk |
Pathogenic |
Macrocephaly, Abnormal facial shape |
| RS2069070395 |
NLRP7
|
Health Risk |
Pathogenic |
Hydatidiform mole, recurrent |
| RS2069103320 |
PAFAH1B1
|
Health Risk |
Pathogenic |
Lissencephaly, Lissencephaly |
| RS2069116238 |
NLRP7
|
Health Risk |
Pathogenic |
Hydatidiform mole, Hydatidiform mole |